{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Apixaban+%2B+Placebo", "query": { "intervention": "Apixaban + Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Apixaban+%2B+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T07:55:06.541Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00320255", "title": "A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombosis", "Cancer", "Pulmonary Embolism" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 130, "start_date": "2006-06", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2016-08-16", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320255" }, { "nct_id": "NCT00831441", "title": "Phase III Acute Coronary Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7484, "start_date": "2009-03", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-01-27", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 221, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00831441" }, { "nct_id": "NCT00371683", "title": "Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Deep Vein Thrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Enoxaparin + Placebo", "type": "DRUG" }, { "name": "Apixaban + Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3608, "start_date": "2006-11", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2015-12-30", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00371683" }, { "nct_id": "NCT07626411", "title": "Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation (AF)" ], "interventions": [ { "name": "REGN7508", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15364, "start_date": "2026-08-10", "completion_date": "2029-12-10", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 8, "location_summary": "Dothan, Alabama • Newport Beach, California • Pasadena, California + 5 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Newport Beach", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Pensacola", "state": "Florida" }, { "city": "West Monroe", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07626411" }, { "nct_id": "NCT02378623", "title": "Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Patent Foramen Ovale", "Cardiac Implantable Electronic Device" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2015-05", "completion_date": "2020-01", "has_results": false, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02378623" }, { "nct_id": "NCT02207725", "title": "A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Andexanet", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 68, "start_date": "2014-03", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02207725" }, { "nct_id": "NCT03310021", "title": "A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Andexanet alfa", "type": "BIOLOGICAL" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Edoxaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 108, "start_date": "2017-08-28", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310021" }, { "nct_id": "NCT00457002", "title": "Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 6758, "start_date": "2007-06", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-12-08", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00457002" }, { "nct_id": "NCT01758432", "title": "Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "PRT064445/Apixaban", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo/Apixaban", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 54, "start_date": "2012-12", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01758432" }, { "nct_id": "NCT03083704", "title": "A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Andexanet alfa (Gen 1 Process 2)", "type": "BIOLOGICAL" }, { "name": "Apixaban 5 MG", "type": "DRUG" }, { "name": "Rivaroxaban 20 MG", "type": "DRUG" }, { "name": "Enoxaparin sodium", "type": "DRUG" }, { "name": "Edoxaban 60 MG", "type": "DRUG" }, { "name": "Andexanet alfa (Gen 2)", "type": "BIOLOGICAL" }, { "name": "Andexanet alfa (Gen 1 Process 3)", "type": "BIOLOGICAL" }, { "name": "Apixaban 10 MG", "type": "DRUG" }, { "name": "Rivaroxaban 10 MG", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 153, "start_date": "2017-02-26", "completion_date": "2017-09-28", "has_results": false, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-09-14T07:55:06.541Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03083704" } ] }